Sun Pharmaceutical Industries — 360° view

Sun Pharmaceutical Industries, a company in the Pharmaceuticals industry, reported revenue of ₹16,199 crore and net profit of ₹1,995 crore for the September 2026 quarter.

Sun Pharmaceutical Industries (NSE: SUNPHARMA) closed at ₹1,884.90 on 20 Nov 2026, up 6.0% over the past year. Its market capitalisation is ₹4,52,251 crore and it trades at 36.8 times earnings.

Share price
₹1,884.90 (20 Nov 2026)
Market cap
₹4,52,251 Cr (20 Nov 2026)
P/E
36.76 (20 Nov 2026)
Revenue
₹16,199 Cr (September 2026 quarter)
Net profit
₹1,995 Cr (September 2026 quarter)
ROCE
20.5% (FY26)
ROE
16.0% (FY26)
Book value
₹372 (FY26)
Dividend yield
0.85% (last 12 months to 20 Nov 2026)
52-week high / low
₹2,046.90 / ₹1,583.70 (20 Nov 2026)
1-year return
6.0% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: SUNPHARMA

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.